<DOC>
	<DOCNO>NCT02267382</DOCNO>
	<brief_summary>VT-1161 novel , oral inhibitor fungal lanosterol demethylase ( CYP51 ) . In vitro vivo pharmacology study demonstrate VT-1161 highly active Candida albicans also non-albicans Candida specie cause vulvovaginal candidiasis . VT-1161 highly selective fungal CYP51 , data suggests may avoid side-effect profile limit use commonly prescribed antifungal agent treatment recurrent yeast infection .</brief_summary>
	<brief_title>A Study Evaluate Oral VT-1161 Treatment Patients With Recurrent Vaginal Candidiasis ( Yeast Infection )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<criteria>Key Clinical diagnosis symptomatic acute VVC 3 episode acute VVC past 12 month Positive KOH Minimum composite vulvovaginal sign symptom score â‰¥3 Screening Composite vulvovaginal sign symptom score &lt; 3 Baseline Must able swallow tablet Key Evidence major organ system disease Presence history another vaginal vulvar condition ( ) History cervical cancer Poorly control diabetes mellitus Pregnant Recent use topical systemic antifungal drug Recent use immunosuppressive system corticosteriod therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>